Table 1.

Demographics and clinicopathological features of the primary tumor and recurrence according to treatment of the recurrence.

	Total Recurrences N=92	CHT alone N= 41	Surgery N = 18	Supportive Care N = 33
Primary tumor location
- Intrahepatic CC	34 (37%)	15 (36.6%)	6 (33.3%)	13 (39.4%)	p= 0.49
- Perihiliar CC	42 (45,6%)	17 (41.5%)	11 (61.1%)	14 (42.4%)
- Distal CC	16 (17.4%)	9 (21.9%)	1 (5.6%)	6 (18.2%)
Sex
- Male	57 (62%)	26 (63.4%)	14 (77.8%)	17 (51.5%)	p= 0.209
- Female	35 (38%)	15 (36.6%)	4 (22.2%)	16 (48.5%)
Age (years)	64,1 (31-90)	66 (31-76)	63,5 (48-73)	66,5 (41-90)	p= 0.879
ASA
- I - II	43 (46.7%)	21 (51.2%)	7 (38.9%)	15 (45.5%)	p= 0.79
- III - IV	49 (53.3%)	20 (48.8%)	11 (61.1%)	18 (54.5%)
Primary Tumor T
- T1 - T2	61 (66.3%)	26 (63.4%)	14 (77.8%)	21 (63.6%)	p= 0.62
- T3 - T4	31 (33.7%)	15 (36.6%)	4 (22.2%)	12 (36.4%)
Primary Tumor N
- N0	64 (69.6%)	27 (65.8%)	12 (66.7%)	25 (75.8%)	p= 0.79
- N+	28 (30.4%)	14 (34.2%)	6 (33.3%)	8 (24.2%)
Primary Tumor M
- M0	85 (92.4%)	36 (87.8%)	18 (100%)	31 (93.9%)	p= 0.24
- M+	7 (7.6%)	5 (12.2%)	0 (0%)	2 (6.1%)
Primary Tumor resection
- R0	62 (67.4%)	28 (68.3%)	13 (72.2%)	21(63.6%)	p= 0.52
- R1	28 (30.4%)	12 (29.3%)	4 (22.2%)	12 (36.4%)
- R2	2 (2.2%)	1 (2.4%)	1 (5.6%)	0 (0%)
Adjuvant CHT treatment	32 (34.8%)	19 (43.2%)	8 (44.4%)	5 (12.2%)	p= 0.003*
Site of Recurrence
- Locoregional	32 (34.8%)	13 (31.7%)	9 (50%)	10 (30.3%)	p= 0.07
- Hepatic	32 (34.8%)	18 (43.9%)	4 (22.2%)	10 (30.3%)
- Distant	26 (28.2%)	10 (24.4%)	3 (16.7%)	13 (39.4%)
- Multiple	2 (2.2%)	0 (0%)	2 (11.1%)	0 (0%)
Time to recurrence (months)	11.04 (0-131)	9.9 (0-66)	18.9 (2-82)	11.5 (0-131)	p=0.40

*Best-supportive treatment vs CHT or surgery.

CC, Cholangiocarcinoma; CHT, Chemotherapy.

Data is shown in number (percentage) and median (range).